BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 14559038)

  • 1. Prenatal diagnosis after ART success: the role of early combined screening tests in counselling pregnant patients.
    Ghisoni L; Ferrazzi E; Castagna C; Levi Setti PE; Masini AC; Pigni A
    Placenta; 2003 Oct; 24 Suppl B():S99-S103. PubMed ID: 14559038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of a 'vanishing twin' on biochemical and ultrasound first trimester screening markers for Down's syndrome in pregnancies conceived by assisted reproductive technology.
    Gjerris AC; Loft A; Pinborg A; Christiansen M; Tabor A
    Hum Reprod; 2009 Jan; 24(1):55-62. PubMed ID: 18835870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First trimester screening with free beta-hCG, PAPP-A and nuchal translucency in pregnancies conceived with assisted reproduction.
    Orlandi F; Rossi C; Allegra A; Krantz D; Hallahan T; Orlandi E; Macri J
    Prenat Diagn; 2002 Aug; 22(8):718-21. PubMed ID: 12210583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multivariate analysis identifies the estradiol level at ovulation triggering as an independent predictor of the first trimester pregnancy-associated plasma protein-A level in IVF/ICSI pregnancies.
    Giorgetti C; Vanden Meerschaut F; De Roo C; Saunier O; Quarello E; Hairion D; Penaranda G; Chabert-Orsini V; De Sutter P
    Hum Reprod; 2013 Oct; 28(10):2636-42. PubMed ID: 23887070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined ultrasound and biochemical screening for Down's syndrome in the first trimester: a Scottish multicentre study.
    Crossley JA; Aitken DA; Cameron AD; McBride E; Connor JM
    BJOG; 2002 Jun; 109(6):667-76. PubMed ID: 12118646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prenatal screening for fetal aneuploidy in singleton pregnancies.
    Chitayat D; Langlois S; Douglas Wilson R; ;
    J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-trimester screening for trisomy 21 in singleton pregnancies achieved by assisted reproduction.
    Liao AW; Heath V; Kametas N; Spencer K; Nicolaides KH
    Hum Reprod; 2001 Jul; 16(7):1501-4. PubMed ID: 11425838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maternal serum free-beta-chorionic gonadotrophin, pregnancy-associated plasma protein-A and fetal nuchal translucency thickness at 10-13(+6) weeks in relation to co-variables in pregnant Saudi women.
    Ardawi MS; Nasrat HA; Rouzi AA; Qari MH; Al-Qahtani MH; Abuzenadah AM
    Prenat Diagn; 2007 Apr; 27(4):303-11. PubMed ID: 17269128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
    Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
    Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maternal serum hyperglycosylated human chorionic gonadotrophin (HhCG) in the first trimester of pregnancies affected by Down syndrome, using a sialic acid-specific lectin immunoassay.
    Spencer K; Talbot JA; Abushoufa RA
    Prenat Diagn; 2002 Aug; 22(8):656-62. PubMed ID: 12210572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frontomaxillary facial angle in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks.
    Borenstein M; Persico N; Kagan KO; Gazzoni A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jul; 32(1):5-11. PubMed ID: 18512854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
    Cicero S; Bindra R; Rembouskos G; Spencer K; Nicolaides KH
    Prenat Diagn; 2003 Apr; 23(4):306-10. PubMed ID: 12673635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-trimester combined screening for trisomy 21 at 7-14 weeks' gestation.
    Wright D; Spencer K; Kagan K K; Tørring N; Petersen OB; Christou A; Kallikas J; Nicolaides KH
    Ultrasound Obstet Gynecol; 2010 Oct; 36(4):404-11. PubMed ID: 20658511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additive effect of factors related to assisted conception on the reduction of maternal serum pregnancy-associated plasma protein A concentrations and the increased false-positive rates in first-trimester Down syndrome screening.
    Bellver J; Casanova C; Garrido N; Lara C; Remohí J; Pellicer A; Serra V
    Fertil Steril; 2013 Nov; 100(5):1314-20. PubMed ID: 23891271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
    Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK
    J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study.
    von Kaisenberg CS; Gasiorek-Wiens A; Bielicki M; Bahlmann F; Meyberg H; Kossakiewicz A; Pruggmayer M; Kamin G; Fritzer E; Harris C; Arnold N;
    J Matern Fetal Neonatal Med; 2002 Aug; 12(2):89-94. PubMed ID: 12420837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of pregnancy-associated plasma protein A (PAPP-A) and free beta subunit of human chorionic gonadotropin (beta hCG) levels and sonographic assesement of fetal nuchal translucency (NT) in singleton pregnancies between 11 and 14 weeks of gestation--Polish multi-centre research].
    Borowski D; Czuba B; Cnota W; Hincz P; Czekierdowski A; Gajewska J; Jaczyńska R; Ceran A; Włoch A; Wyrwas D; Wiełgoś M; Szymusik I; Szaflik K; Sodowski K
    Ginekol Pol; 2007 May; 78(5):384-7. PubMed ID: 17867331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for triploidy by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation.
    Spencer K; Liao AW; Skentou H; Cicero S; Nicolaides KH
    Prenat Diagn; 2000 Jun; 20(6):495-9. PubMed ID: 10861716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.